Digest Network Come funziona
Network
/
Società
Re
Non verificato

ReCode Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

9 comunicati stampa

Guarda tutti i comunicati
17/11/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis
Fonte
ReCode Therapeutics
Emittente
Business Wire
1.00
0
29/09/2025
Mercato del lavoro
Eventi
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Sanità
ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update
Fonte
ReCode Therapeutics
Emittente
Business Wire
1.00
0
25/03/2025
Industria
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT2100 for the Treatment of Cystic Fibrosis
Fonte
ReCode Therapeutics
Emittente
Business Wire
1.00
0
18/11/2024
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
ReCode Therapeutics Announces Additional Funding From the Cystic Fibrosis Foundation to Accelerate Development of Novel Gene Correction Therapeutics to Treat Cystic Fibrosis
Fonte
ReCode Therapeutics
Emittente
Business Wire
1.00
0
01/10/2024
Mercato del lavoro
Salute
Biotecnologia
Scienza
Sanità
ReCode Announces Two Key Additions to Scientific Advisory Board
Fonte
ReCode Therapeutics
Emittente
Business Wire
1.00
0
26/09/2024
Eventi
Industria
Biotecnologia
Salute
Medicina - Varie
ReCode Therapeutics Presents Preclinical Data from its Cystic Fibrosis Program at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston
Fonte
ReCode Therapeutics
Emittente
Business Wire
1.00
0
26/09/2024
Industria
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis
Fonte
ReCode Therapeutics
Emittente
Business Wire
1.00
0
25/09/2024
Eventi
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
ReCode Therapeutics to Participate in Upcoming Investor Conferences
Fonte
ReCode Therapeutics
Emittente
Business Wire
1.00
0
27/06/2024
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia
Fonte
ReCode Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0